ziprasidone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2865 146939-27-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ziprasidone
  • zaprasidone
  • ziprasidone hydrochloride
  • ziprasidone mesylate
  • geodon
  • ziprasidone HCl
  • ziprasidone mesilate
a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone
  • Molecular weight: 412.94
  • Formula: C21H21ClN4OS
  • CLOGP: 4.21
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 48.47
  • ALOGS: -4.76
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.36 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 5, 2001 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tardive dyskinesia 1011.60 36.39 184 2695 1520 2353686
Dystonia 743.22 36.39 148 2731 2046 2353160
Completed suicide 683.55 36.39 216 2663 20818 2334388
Neuroleptic malignant syndrome 536.55 36.39 112 2767 1968 2353238
Extrapyramidal disorder 494.75 36.39 107 2772 2240 2352966
Sedation 482.98 36.39 112 2767 3250 2351956
Electrocardiogram QT prolonged 443.69 36.39 124 2755 7690 2347516
Dyskinesia 428.71 36.39 109 2770 4680 2350526
Akathisia 345.06 36.39 75 2804 1599 2353607
Tremor 339.72 36.39 128 2751 20533 2334673
Drug hypersensitivity 274.27 36.39 140 2739 46503 2308703
Agitation 262.34 36.39 90 2789 10961 2344245
Anxiety 253.99 36.39 115 2764 29244 2325962
Weight increased 253.53 36.39 106 2773 22231 2332975
Suicide attempt 245.05 36.39 86 2793 11196 2344010
Drug ineffective 243.99 36.39 171 2708 101453 2253753
Cardio-respiratory arrest 234.69 36.39 79 2800 9067 2346139
Somnolence 231.90 36.39 101 2778 23384 2331822
Blood prolactin abnormal 221.74 36.39 34 2845 76 2355130
Mania 220.20 36.39 56 2823 2384 2352822
Parkinsonism 214.94 36.39 50 2829 1455 2353751
Depression 211.34 36.39 100 2779 28032 2327174
Anosognosia 210.35 36.39 31 2848 46 2355160
Psychotic disorder 210.12 36.39 62 2817 4617 2350589
Sexual dysfunction 203.62 36.39 37 2842 295 2354911
Insomnia 170.32 36.39 84 2795 25703 2329503
Toxicity to various agents 159.68 36.39 87 2792 32667 2322539
Disturbance in social behaviour 154.26 36.39 27 2852 169 2355037
Suicidal ideation 154.18 36.39 61 2818 11026 2344180
Torsade de pointes 151.80 36.39 41 2838 2205 2353001
Cardiac arrest 146.36 36.39 64 2815 14866 2340340
Metabolic disorder 145.88 36.39 31 2848 587 2354619
Respiratory arrest 137.36 36.39 48 2831 6130 2349076
Condition aggravated 131.46 36.39 76 2803 31903 2323303
Hallucination 124.40 36.39 48 2831 8100 2347106
Paranoia 121.69 36.39 34 2845 2073 2353133
Seizure 116.32 36.39 64 2815 24402 2330804
Dysphagia 116.12 36.39 52 2827 12753 2342453
Delusion 113.24 36.39 32 2847 2033 2353173
Personality change 112.02 36.39 27 2852 914 2354292
Loss of consciousness 111.55 36.39 57 2822 18710 2336496
Swollen tongue 109.17 36.39 39 2840 5304 2349902
Overdose 108.38 36.39 57 2822 19850 2335356
Galactorrhoea 108.22 36.39 28 2851 1271 2353935
Restlessness 107.36 36.39 37 2842 4526 2350680
Feeling abnormal 104.73 36.39 59 2820 23522 2331684
Blood prolactin increased 103.65 36.39 26 2853 1041 2354165
Syncope 102.44 36.39 52 2827 16823 2338383
Musculoskeletal stiffness 96.13 36.39 45 2834 12202 2343004
Blood glucose increased 95.97 36.39 45 2834 12245 2342961
Muscle twitching 91.44 36.39 29 2850 2736 2352470
Abnormal behaviour 86.96 36.39 32 2847 4728 2350478
Hallucination, auditory 85.11 36.39 26 2853 2166 2353040
Dizziness 83.60 36.39 73 2806 58592 2296614
Schizophrenia 83.36 36.39 23 2856 1336 2353870
Aggression 83.12 36.39 31 2848 4755 2350451
Hyperprolactinaemia 82.26 36.39 20 2859 702 2354504
Muscle rigidity 80.93 36.39 24 2855 1807 2353399
Gait disturbance 80.50 36.39 49 2830 22496 2332710
Coma 76.40 36.39 35 2844 9021 2346185
Withdrawal syndrome 74.38 36.39 26 2853 3311 2351895
Dyspnoea 74.24 36.39 78 2801 78655 2276551
Mental disorder 73.41 36.39 27 2852 3980 2351226
Orthostatic hypertension 71.32 36.39 12 2867 57 2355149
Insurance issue 70.86 36.39 16 2863 404 2354802
Rash 70.86 36.39 67 2812 59491 2295715
Catatonia 69.22 36.39 18 2861 832 2354374
Weight decreased 67.87 36.39 48 2831 28323 2326883
Oculogyric crisis 67.85 36.39 15 2864 343 2354863
Cardiometabolic syndrome 67.71 36.39 14 2865 230 2354976
Confusional state 67.22 36.39 45 2834 24299 2330907
Psychomotor hyperactivity 67.03 36.39 21 2858 1901 2353305
Bipolar disorder 65.84 36.39 19 2860 1299 2353907
Serotonin syndrome 65.39 36.39 24 2855 3516 2351690
Tachycardia 64.60 36.39 38 2841 16371 2338835
Nausea 64.05 36.39 86 2793 112103 2243103
Drug intolerance 62.64 36.39 35 2844 13682 2341524
Intentional overdose 60.33 36.39 32 2847 11289 2343917
Blood creatine phosphokinase increased 60.08 36.39 25 2854 5111 2350095
Thinking abnormal 58.57 36.39 19 2860 1923 2353283
Intentional product misuse 56.80 36.39 29 2850 9460 2345746
Asthenia 56.14 36.39 53 2826 46873 2308333
Fatigue 56.07 36.39 70 2809 84803 2270403
Vomiting 55.38 36.39 64 2815 71538 2283668
Vision blurred 55.19 36.39 33 2846 14635 2340571
Dysarthria 55.16 36.39 25 2854 6277 2348929
Trismus 54.42 36.39 15 2864 867 2354339
Drug interaction 53.30 36.39 42 2837 29121 2326085
Drug withdrawal syndrome 53.26 36.39 25 2854 6796 2348410
Muscle spasms 52.72 36.39 37 2842 21529 2333677
Treatment noncompliance 51.76 36.39 23 2856 5511 2349695
Diabetes mellitus 51.02 36.39 25 2854 7470 2347736
Visual impairment 50.96 36.39 29 2850 11726 2343480
Ventricular tachycardia 50.42 36.39 19 2860 2992 2352214
Dry mouth 48.74 36.39 25 2854 8228 2346978
Irritability 48.47 36.39 23 2856 6404 2348802
Movement disorder 47.92 36.39 18 2861 2810 2352396
Bruxism 47.42 36.39 13 2866 736 2354470
Lethargy 47.41 36.39 25 2854 8705 2346501
Product substitution issue 47.19 36.39 21 2858 5048 2350158
Muscle tightness 46.92 36.39 16 2863 1889 2353317
Torticollis 46.03 36.39 11 2868 358 2354848
Affective disorder 45.76 36.39 13 2866 839 2354367
Cogwheel rigidity 44.97 36.39 10 2869 235 2354971
Depressed level of consciousness 44.80 36.39 23 2856 7581 2347625
Rhabdomyolysis 44.55 36.39 22 2857 6682 2348524
Poisoning 44.35 36.39 17 2862 2803 2352403
Rabbit syndrome 43.85 36.39 8 2871 65 2355141
Adverse drug reaction 42.95 36.39 23 2856 8260 2346946
Generalised tonic-clonic seizure 42.89 36.39 20 2859 5352 2349854
Death 42.64 36.39 60 2819 81408 2273798
Exposure via ingestion 42.22 36.39 12 2867 776 2354430
Obesity 42.17 36.39 14 2865 1522 2353684
Mental status changes 42.16 36.39 20 2859 5562 2349644
Panic attack 42.06 36.39 18 2861 3938 2351268
Hypomania 41.93 36.39 12 2867 795 2354411
Fall 41.30 36.39 45 2834 47054 2308152
Photophobia 40.35 36.39 15 2864 2274 2352932
Appetite disorder 40.07 36.39 11 2868 626 2354580
Disorientation 39.65 36.39 20 2859 6352 2348854
Drug dependence 39.61 36.39 16 2863 3029 2352177
Incorrect dose administered 39.56 36.39 23 2856 9672 2345534
Obsessive-compulsive disorder 39.55 36.39 11 2868 657 2354549
Constipation 39.17 36.39 31 2848 21598 2333608
Sjogren's syndrome 39.15 36.39 12 2867 1009 2354197
Tenderness 39.13 36.39 14 2865 1904 2353302
Skin warm 39.07 36.39 11 2868 687 2354519
Tongue disorder 38.02 36.39 12 2867 1111 2354095
Myalgia 37.10 36.39 31 2848 23302 2331904
Haemorrhagic diathesis 37.08 36.39 10 2869 532 2354674
Restless legs syndrome 36.82 36.39 14 2865 2257 2352949
Speech disorder 36.48 36.39 19 2860 6445 2348761
Sleep disorder 36.41 36.39 19 2860 6470 2348736

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 487.01 41.40 106 1979 1908 1742788
Neuroleptic malignant syndrome 434.72 41.40 105 1980 3043 1741653
Completed suicide 344.08 41.40 127 1958 16185 1728511
Extrapyramidal disorder 341.78 41.40 82 2003 2295 1742401
Tardive dyskinesia 331.01 41.40 70 2015 1082 1743614
Dyskinesia 284.45 41.40 78 2007 3741 1740955
Agitation 281.36 41.40 99 1986 10927 1733769
Electrocardiogram QT prolonged 247.16 41.40 76 2009 5469 1739227
Sedation 227.69 41.40 64 2021 3353 1741343
Anxiety 227.52 41.40 93 1992 15434 1729262
Somnolence 217.41 41.40 92 1993 16647 1728049
Drug ineffective 211.09 41.40 140 1945 63661 1681035
Psychotic disorder 207.11 41.40 65 2020 4991 1739705
Aggression 199.51 41.40 71 2014 8044 1736652
Akathisia 196.69 41.40 47 2038 1281 1743415
Priapism 192.14 41.40 47 2038 1417 1743279
Weight increased 190.27 41.40 75 2010 11282 1733414
Insomnia 177.00 41.40 79 2006 16197 1728499
Swollen tongue 157.36 41.40 46 2039 2762 1741934
Suicidal ideation 152.19 41.40 59 2026 8459 1736237
Tremor 137.03 41.40 62 2023 13069 1731627
Mania 124.13 41.40 36 2049 2097 1742599
Toxicity to various agents 123.06 41.40 75 2010 29066 1715630
Bruxism 118.49 41.40 24 2061 293 1744403
Homicidal ideation 117.96 41.40 27 2058 604 1744092
Hallucination 112.65 41.40 47 2038 8123 1736573
Cardiac arrest 110.87 41.40 57 2028 15873 1728823
Catatonia 108.88 41.40 27 2058 858 1743838
Speech disorder 108.54 41.40 39 2046 4509 1740187
Drug hypersensitivity 101.96 41.40 53 2032 15082 1729614
Decreased eye contact 99.62 41.40 16 2069 42 1744654
Blood creatine phosphokinase increased 99.22 41.40 44 2041 8812 1735884
Oppositional defiant disorder 96.61 41.40 16 2069 54 1744642
Paranoia 93.12 41.40 29 2056 2152 1742544
Psychomotor hyperactivity 92.84 41.40 28 2057 1865 1742831
Parkinsonism 88.08 41.40 25 2060 1344 1743352
Seizure 87.08 41.40 53 2032 20388 1724308
Depression 86.18 41.40 49 2036 16620 1728076
Hallucination, auditory 85.58 41.40 27 2058 2090 1742606
Condition aggravated 85.41 41.40 53 2032 21097 1723599
Anosognosia 83.07 41.40 14 2071 54 1744642
Oculogyric crisis 81.15 41.40 18 2067 347 1744349
Muscle rigidity 80.68 41.40 25 2060 1823 1742873
Suicide attempt 80.48 41.40 36 2049 7345 1737351
Euphoric mood 80.38 41.40 21 2064 824 1743872
Serotonin syndrome 78.28 41.40 27 2058 2761 1741935
Feeling abnormal 77.70 41.40 40 2045 11126 1733570
Musculoskeletal stiffness 74.90 41.40 32 2053 5844 1738852
Sydenham's chorea 72.50 41.40 10 2075 3 1744693
Hyperhidrosis 70.71 41.40 39 2046 12449 1732247
Restlessness 70.22 41.40 28 2057 4293 1740403
Drug interaction 69.71 41.40 52 2033 27906 1716790
Crying 68.81 41.40 21 2064 1454 1743242
Dizziness 68.55 41.40 56 2029 34305 1710391
Coordination abnormal 68.50 41.40 21 2064 1476 1743220
Trismus 68.34 41.40 17 2068 546 1744150
Delusion 68.07 41.40 23 2062 2208 1742488
Cardio-respiratory arrest 66.68 41.40 34 2051 9259 1735437
Bipolar disorder 63.23 41.40 17 2068 745 1743951
Respiratory arrest 62.09 41.40 28 2057 5811 1738885
Obsessive-compulsive disorder 61.84 41.40 17 2068 811 1743885
Tachycardia 59.54 41.40 35 2050 12593 1732103
Choreoathetosis 58.16 41.40 12 2073 161 1744535
Schizophrenia 58.13 41.40 20 2065 2026 1742670
Sleep disorder 58.01 41.40 24 2061 4039 1740657
Blood prolactin abnormal 57.90 41.40 10 2075 46 1744650
Irritability 57.14 41.40 26 2059 5506 1739190
Antipsychotic drug level below therapeutic 57.10 41.40 12 2073 177 1744519
Nervousness 56.47 41.40 20 2065 2207 1742489
Therapeutic product effect variable 55.32 41.40 11 2074 121 1744575
Disinhibition 55.15 41.40 13 2072 331 1744365
Thinking abnormal 54.11 41.40 17 2068 1295 1743401
Depressed mood 54.09 41.40 21 2064 2995 1741701
Rhabdomyolysis 52.95 41.40 31 2054 11059 1733637
Treatment noncompliance 52.31 41.40 24 2061 5177 1739519
Loss of consciousness 51.79 41.40 34 2051 14841 1729855
Abnormal behaviour 50.75 41.40 25 2060 6317 1738379
Overdose 50.56 41.40 35 2050 16666 1728030
Increased appetite 50.33 41.40 15 2070 956 1743740
Vision blurred 49.55 41.40 27 2058 8396 1736300
Anger 49.36 41.40 19 2066 2647 1742049
Blood glucose increased 48.98 41.40 29 2056 10555 1734141
Lethargy 47.80 41.40 25 2060 7159 1737537
Torticollis 46.22 41.40 11 2074 292 1744404
Nausea 46.15 41.40 54 2031 51142 1693554
Gynaecomastia 46.02 41.40 17 2068 2115 1742581
Myopathy toxic 44.39 41.40 9 2076 110 1744586
Disturbance in social behaviour 44.25 41.40 10 2075 210 1744486
Dyspnoea 43.77 41.40 53 2032 52006 1692690
Fatigue 43.18 41.40 52 2033 50729 1693967
Erectile dysfunction 42.87 41.40 20 2065 4477 1740219
Dysphagia 42.24 41.40 26 2059 10142 1734554

Pharmacologic Action:

SourceCodeDescription
ATC N05AE04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Indole derivatives
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
CHEBI has role CHEBI:35471 psychotropic drug
CHEBI has role CHEBI:37956 histamine antagonist
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:35476 antipsychotic agent
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Agitation associated with Schizophrenia indication
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Depression Treatment Adjunct off-label use
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Bradycardia contraindication 48867003
Hyperlipidemia contraindication 55822004 DOID:1168
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Metabolic syndrome X contraindication 237602007 DOID:14221
Neutropenic disorder contraindication 303011007 DOID:1227
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Acquired torsion dystonia contraindication 433493000
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.26 acidic
pKa2 7.35 Basic
pKa3 0.27 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.32 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.59 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.54 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 7.56 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.05 PDSP
Histamine H2 receptor GPCR Ki 5.46 PDSP
D(1B) dopamine receptor GPCR Ki 6.82 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.11 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.32 PDSP
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.89 WOMBAT-PK
5-hydroxytryptamine receptor 1E GPCR Ki 6.44 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.40 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 8.70 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 6.55 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.33 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 8.30 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.22 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR EC50 8.47 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter IC50 7 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.92 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.30 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 7.36 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.80 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.80 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.52 PDSP
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
D(1A) dopamine receptor GPCR Ki 8.02 CHEMBL
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.14 WOMBAT-PK
Transporter Transporter Ki 7.32 CHEMBL
Histamine H1 receptor GPCR IC50 6.82 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.96 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.30 CHEMBL
D(2) dopamine receptor GPCR Ki 8.32 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.38 CHEMBL
Histamine H1 receptor GPCR Ki 7.80 CHEMBL

External reference:

IDSource
4021249 VUID
N0000148690 NUI
C0380393 UMLSCUI
D02100 KEGG_DRUG
216X081ORU UNII
138982-67-9 SECONDARY_CAS_RN
7155 INN_ID
373389002 SNOMEDCT_US
4021249 VANDF
009104 NDDF
d04747 MMSL
115698 RXNORM
409356003 SNOMEDCT_US
CHEMBL708 ChEMBL_ID
DB00246 DRUGBANK_ID
CHEMBL1712 ChEMBL_ID
CHEBI:10119 CHEBI
CHEMBL1200997 ChEMBL_ID
CHEMBL1375743 ChEMBL_ID
CHEMBL3989833 ChEMBL_ID
60854 PUBCHEM_CID
59 IUPHAR_LIGAND_ID
C092292 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0052 CAPSULE 20 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0054 CAPSULE 40 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0056 CAPSULE 60 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0058 CAPSULE 80 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-1203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 19 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3920 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3960 CAPSULE 20 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3980 CAPSULE 60 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3990 CAPSULE 80 mg ORAL NDA 20 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7703 CAPSULE 80 mg ORAL ANDA 20 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2164 CAPSULE 20 mg ORAL ANDA 18 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2166 CAPSULE 40 mg ORAL ANDA 18 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2167 CAPSULE 60 mg ORAL ANDA 18 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2168 CAPSULE 80 mg ORAL ANDA 18 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6269 CAPSULE 20 mg ORAL ANDA 19 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6270 CAPSULE 40 mg ORAL ANDA 19 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6271 CAPSULE 60 mg ORAL ANDA 19 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6272 CAPSULE 80 mg ORAL ANDA 19 sections
GEODON HUMAN PRESCRIPTION DRUG LABEL 1 16590-895 CAPSULE 20 mg ORAL NDA 20 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-835 CAPSULE 20 mg ORAL ANDA 19 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-836 CAPSULE 40 mg ORAL ANDA 19 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-837 CAPSULE 60 mg ORAL ANDA 19 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-838 CAPSULE 80 mg ORAL ANDA 19 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-060 CAPSULE 20 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-061 CAPSULE 40 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-062 CAPSULE 60 mg ORAL NDA 20 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-063 CAPSULE 80 mg ORAL NDA 20 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33342-144 CAPSULE 20 mg ORAL ANDA 20 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33342-145 CAPSULE 40 mg ORAL ANDA 20 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33342-146 CAPSULE 60 mg ORAL ANDA 20 sections